Pre-market Hot Trades in US Stocks
Rocket Lab is down 4.17% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 12, Rocket Lab announced the acquisition of Motiv Space Systems, filling a critical gap in its vertical integration strategy and driving up the stock price. The acquisition amount is $40 million in cash plus up to $20 million in stock, which is expected to expand the company's role in the lunar, Mars, and orbital services markets.
</li>
<li>
On May 13, ARK Invest sold Rocket Lab shares after the stock reached an all-time high, with Cathie Wood reallocating funds to AI, biotechnology, and defense stocks. This move reflects interest in a SpaceX IPO and analysts' divergence on Rocket Lab's long-term valuation.
</li>
<li>
On May 14, Needham raised Rocket Lab's target price to $120 and maintained a buy rating, driving the stock price up. The company's first-quarter revenue exceeded expectations, with record backlog orders and new multi-launch contracts further boosting market confidence. Investment enthusiasm in the space industry is heating up, with significant capital inflows.
</li>
</ol>
Teradyne is down 3.87% in pre-market trading. Based on recent news:
<ol>
<li>
On May 12, Teradyne's Vice President and General Counsel Ryan E. Driscoll sold 680 shares of common stock at a price of $377.6 per share. This transaction reduced his holdings to 7,665 shares. This news may raise market concerns about executive confidence in the company, leading to a drop in stock price.
</li>
<li>
On May 15, despite Teradyne's annualized return of 17.22% over the past 20 years, analysts believe there are five stocks with higher investment value. This rating may weaken investor confidence in Teradyne, further pressuring the stock price.
</li>
<li>
On May 13, although Teradyne is currently rated as &#34;moderate buy,&#34; top analysts believe there are five stocks that are more worthy of investment. This viewpoint may lead some investors to shift to other stocks, affecting Teradyne's stock price. The overall market performance is stable, and investors need to pay attention to industry dynamics.
</li>
</ol>
Top Gainers in Pre-market US Stocks
HCW Biologics is up 196.74% in pre-market trading. Based on recent news:
<ol>
<li>
On May 14, HCW Biologics released its financial report for the first quarter of 2026, showing earnings per share of $0.37, exceeding market expectations. This positive news significantly boosted the stock price.
</li>
<li>
On May 14, HCW Biologics announced that its research in IND activation found that HCW11-040 can prevent bronchopulmonary dysplasia (BPD), with expectations to complete the research and submit the IND application in the second half of 2027. This R&amp;D progress has enhanced market confidence in the company's future development
On May 14, analysts rated HCW Biologics as &#34;Buy&#34; and set a 12-month target price of $2.00, indicating a potential upside of 472.4% compared to the closing price of $0.35 on May 13. This optimistic analyst rating further propelled the stock price upward. The biotechnology sector has performed strongly recently, with heightened investor sentiment.
</li>
</ol>
Dreamland pre-market rose 114.96%. Based on recent key news:
<ol>
<li>
On May 12, Dreamland signed a memorandum of understanding with LinkFung Innovation to explore AI platform development. This move is seen as part of the company's strategic expansion, driving the stock price up.
</li>
<li>
On May 13, Dreamland's stock price surged 126.92%, with a trading volume of approximately $219 million, indicating extreme capital inflow, and technical indicators triggered bullish signals, showing clear market sentiment.
</li>
<li>
On May 14, technical analysis showed the RSI reached 97.75, with the stock price far exceeding key moving averages, reflecting strong market optimism, but there is a risk of a pullback in the short term. There have been no significant positive developments in the film entertainment industry recently.
</li>
</ol>
Auddia pre-market rose 72.13%. Based on recent key news:
<ol>
<li>
On May 15, Auddia submitted an S-4 filing to merge with Thramann Holdings, establishing McCarthy Finney as a unified AI platform. This move is seen as an important step in the company's strategic expansion, significantly boosting the stock price. Source: Reuters
</li>
<li>
On May 12, Auddia's directors and executives participated in a proxy solicitation related to the merger transaction, with relevant information to be disclosed in the S-4 filing. This information increased market confidence in the success of the merger, further stimulating the stock price. Source: Auddia Inc.
</li>
<li>
On May 12, Auddia communicated with investors through its official website, emphasizing the importance of the merger transaction and its impact on the company's future development. This move enhanced investor confidence, driving the stock price up. Source: Auddia Inc. The U.S. stock market has recently experienced increased volatility, and risks need to be monitored
</li>
</ol>

RKLB

Rocket Lab pre-market down 4.17%; Teradyne pre-market down 3.87%; HCW Biologics pre-market up 196.74%; Dreamland pre-market up 114.96%; Auddia pre-market up 72.13%

Price Alert

Rocket Lab

Pre-market hot trades in US stocks: Rocket Lab pre-market down 4.17%; Teradyne pre-market down 3.87%